Peginterferon lambda-1a biosimilar - Nanogen Biopharmaceutical

Drug Profile

Peginterferon lambda-1a biosimilar - Nanogen Biopharmaceutical

Alternative Names: Peglamda; Pegylated interferon lambda 1

Latest Information Update: 29 Dec 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nanogen Biopharmaceutical Co
  • Class Antivirals; Interleukins
  • Mechanism of Action Immunostimulants; Interleukin 29 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Hepatitis C
  • No development reported Hepatitis B

Most Recent Events

  • 13 Dec 2016 Peginterferon lambda-1a biosimilar is still in phase I development for Hepatitis C in Vietnam
  • 01 Jul 2016 Nanogen Biopharmaceuticals completes a phase I trial in Hepatitis C (In volunteers and Treatment-naive patients) in Vietnam (SC)
  • 14 Mar 2014 Early research in Hepatitis B in Vietnam (SC) prior to March 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top